Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session

37MO - Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial


24 Feb 2023


Mini Oral session


Tumour Site

Ovarian Cancer


Lingya Pan


Annals of Oncology (2023) 8 (1suppl_1): 100811-100811. 10.1016/esmoop/esmoop100811


L. Pan1, L. Wu2, J. Zhu3, R. Yin4, J. Wang5, B. Kong6, H. Zheng7, J. Liu8, X. Wu9, L. Wang10, Y. Huang11, K. Wang12, D. Zou13, H. Zhao14, C. Wang15, W. Lu16, A. Lin17, X. Zhen18, W. Hang19, J. Hou20

Author affiliations

  • 1 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing/CN
  • 2 Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN
  • 3 Cancer hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou/CN
  • 4 West China Second University Hospital, Sichuan University/ West China Women's and Children's Hospital, Chengdu/CN
  • 5 Hunan Cancer Hospital, Changsha/CN
  • 6 Qilu Hospital of Shandong University, Jinan/CN
  • 7 Peking University Cancer Hospital & Institute, Beijing/CN
  • 8 Sun Yat-sen University Cancer Center, Guangzhou/CN
  • 9 Fudan University Shanghai Cancer Center, Shanghai/CN
  • 10 Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou/CN
  • 11 Hubei Cancer Hospital, Wuhan/CN
  • 12 TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN
  • 13 Chongqing University Cancer Hospital (Chongqing Cancer Hospital), Chongqing/CN
  • 14 The First Affiliated Hospital of Wenzhou Medical University - NanBaixiang Site, Wenzhou/CN
  • 15 Cancer Hospital of China Medical University (Liaoning Cancer Hospital & Institute), Shenyang/CN
  • 16 Women’s Hospital School of Medicine Zhejiang University, Hangzhou/CN
  • 17 Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou/CN
  • 18 Zai Lab (US) LLC, Cambridge/US
  • 19 Zai Lab (Shanghai) Co., Ltd, Shanghai/CN
  • 20 Zai Laboratory, Shanghai/CN


Login to access the resources on OncologyPRO.

Abstract 37MO


The PRIME (NCT03709316) study was a randomized, double-blind, placebo-controlled, phase 3 trial. Eligible patients were randomised (2:1) to receive niraparib or placebo. Niraparib maintenance therapy with an individualized starting dose (ISD) improved PFS vs placebo (HR 0.45; 95% CI, 0.34–0.60) in Chinese patients with newly diagnosed, advanced ovarian cancer and CR or PR to 1L platinum-based chemotherapy. This post-hoc analysis aims to evaluate niraparib efficacy by the timing of debulking surgery and postoperative residual disease status.


This analysis reports PFS and HRs based on surgical timing (primary debulking surgery [PDS] and interval debulking surgery [IDS]) and residual disease status [optimal(R0/R1) vs suboptimal(R2)]. Median PFS (assessed by BICR) and HRs were obtained using the Kaplan-Meier method and stratified Cox proportional hazards models, respectively.


The DCO date was 30 Sep. 2021. In total, 255 patients were randomized and treated to niraparib (134 PDS, 121 IDS) and 129 to placebo (70 PDS, 59 IDS). The PFS median follow-up was 27.5 months. The efficacy results are shown in the table. Niraparib significantly prolonged PFS compared with placebo irrespective of surgical timing. For PFS, HR 0.63 (95% CI 0.42–0.94, median PFS was not reached in niraparib arm vs. 12.0 months in placebo arm) in patients who underwent PDS; HR = 0.32 (95% CI 0.21-0.48, median PFS in niraparib and placebo arm was 22.3 vs. 5.6 months) in patients undergoing IDS. In niraparib-treated patients, those who underwent PDS and IDS experienced similar rates of grade ≥3 adverse events (TEAEs) (50.7% vs 58.7%) and treatment discontinuation due to AEs (6.7% vs 6.6%).

Figure 1


This subgroup analysis demonstrated that niraparib improved PFS regardless of surgical timing compared with placebo in patients with newly diagnosed advanced ovarian cancer.

Clinical trial identification


Legal entity responsible for the study

Zai Lab.


This study was funded by Zai Lab (Shanghai) Co., Ltd and partially supported by the National Major Scientific and Technological Special Project for Significant New Drugs Development in 2020, China [grant number 2020ZX09101-014].


X. Zhen: Financial Interests, Personal, Stocks/Shares: Zai Lab (Shanghai) Co., Ltd; Financial Interests, Personal, Full or part-time Employment: Zai Lab (Shanghai) Co., Ltd. W. Hang: Financial Interests, Personal, Full or part-time Employment: Zai Lab (Shanghai) Co., Ltd; Financial Interests, Personal, Stocks/Shares: Zai Lab (Shanghai) Co., Ltd. J. Hou: Financial Interests, Personal, Full or part-time Employment: Zai Lab (Shanghai) Co., Ltd; Financial Interests, Personal, Stocks/Shares: Zai Lab (Shanghai) Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.